Radioactive sources embedded in suture are associated with improved postimplant dosimetry in men treated with prostate brachytherapy

Radiotherapy and Oncology

Volumn 65, Issue 2, 2002, Pages 123-127

  Lee, William Robert ^a   DeGuzman, Allan F ^a   Tomlinson, Shannon K ^a   McCullough, David L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Interstitial brachytherapy; Iodine 125; Prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; TREATMENT PLANNING; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; INSTRUMENTATION; METHODOLOGY; PROSTATE TUMOR; RADIOMETRY; SUTURING METHOD; TREATMENT OUTCOME;

RADIOACTIVE IODINE;

AGED; BRACHYTHERAPY; CHI-SQUARE DISTRIBUTION; HUMANS; IODINE RADIOISOTOPES; MALE; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOTHERAPY DOSAGE; SUTURE TECHNIQUES; TREATMENT OUTCOME;

EID: 0036850479     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(02)00305-5     Document Type: Article

References (23)

1. Al-Qaisieh B., Ash D., Bottomley D.M., Carey B.M. Impact of prostate volume evaluation by different observers on CT-based post-implant dosimetry. Radiother Oncol. 62:2002;267-273.
2. Bahnson R.R., Hanks G.E., Huben R.P., et al. NCCN Practice Guidelines for Prostate Cancer. Oncology (Huntingt). 14:2000;111-119.
3. Baird M.C., Holt R.W., Selby T.L. Improvement of transperineal implant dosimetry by intraoperative cystoscopic confirmation of prostate anatomy. J Urol. 164:2000;406-410.
4. Battermann J.J. I-125 implantation for localized prostate cancer: the Utrecht University experience. Radiother Oncol. 57:2000;269-272.
5. Bice W.S. Jr, Prestidge B.R., Grimm P.D., et al. Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys. 41:1998;921-927.
6. Blasko J.C., Grimm P.D., Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol. 3:1993;240-249.
7. Blasko J.C., Grimm P.D., Sylvester J.E., Badiozamani K.R., Hoak D., Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 46:2000;839-850.
8. Critz F.A., Levinson A.K., Williams W.H., Holladay C.T., Griffin V.D., Holladay D.A. Simultaneous radiotherapy for prostate cancer: 125I prostate implant followed by external-beam radiation [see comments]. Cancer J Sci Am. 4:1998;359-363.
9. Fuks Z., Leibel S.A., Wallner K.E., et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys. 21:1991;537-547.
10. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J Clin. 51:2001;15-36.
11. Lee W.R., deGuzman A.F., Bare R.L., Marshall M.G., McCullough D.L. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys. 46:2000;83-88.
12. Lee W.R., Roach M., Michalski J., Moran B., Beyer D. Inter-observer variability leads to significant differences in quantifiers of prostate implant adequacy. Int J Radiat Oncol Biol Phys. 54:(2):2002;457-461.
13. Nag S., Bice W., DeWyngaert K., Prestidge B., Stock R., Yu Y. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 46:2000;221-230.
14. Prestidge B.R., Bice W.S., Walker E.S., Sarosdy M.F. Spatial dose-mapping following transperineal interstitial permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 48:2000;148.
15. Ragde H., Korb L.J., Elgamal A.A., Grado G.L., Nadir B.S. Modern prostate brachytherapy. Cancer. 89:2000;135-141.
16. Roberson P.L., Narayana V., McShan D.L., Winfield R.J., McLaughlin P.W. Source placement error for permanent implant of the prostate. Med Phys. 24:1997;251-257.
17. Sidhu S., Morris W.J., Spadinger I., et al. Prostate brachytherapy postimplant dosimetry: a comparison of prostate quadrants. Int J Radiat Oncol Biol Phys. 52:2002;544-552.
18. Stock R.G., Stone N.N., Kao J., Iannuzzi C., Unger P. The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization. Cancer. 89:2000;1829-1834.
19. Stock R.G., Stone N.N., Lo Y.C., Malhado N., Kao J., DeWyngaert J.K. Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys. 48:2000;899-906.
20. Stock R.G., Stone N.N., Tabert A., Iannuzzi C., DeWyngaert J.K. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:1998;101-108.
21. Tapen E.M., Blasko J.C., Grimm P.D., et al. Reduction of radioactive seed embolization to the lung following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 42:1998;1063-1067.
22. Zelefsky M.J., Whitmore W.F. Jr. Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. J Urol. 158:1997;23-29. discussion 29-30.
23. Zelefsky M.J., Yamada Y., Cohen G., et al. Postimplantation dosimetric analysis of permanent transperineal prostate implantation: improved dose distributions with an intraoperative computer-optimized conformal planning technique. Int J Radiat Oncol Biol Phys. 48:2000;601-608.